0 207

Cited 1 times in

Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity

DC FieldValueLanguage
dc.contributor.author박정수-
dc.contributor.author배수한-
dc.date.accessioned2019-07-23T06:34:03Z-
dc.date.available2019-07-23T06:34:03Z-
dc.date.issued2019-
dc.identifier.issn0891-5849-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170212-
dc.description.abstractNonalcoholic steatohepatitis (NASH) is a common liver disease associated with metabolic disorders, including obesity and type 2 diabetes (T2D). Despite its worldwide prevalence, there are no effective drugs for the treatment of NASH. The progression of NASH is mainly accelerated by reactive oxygen species (ROS)-induced lipotoxicity. The transcription factor known as nuclear factor erythroid 2-related factor 2 (Nrf2) is pivotal for the elimination of ROS. Accordingly, activators of Nrf2 have been implicated as promising therapeutic targets for the treatment of NASH. Niclosamide (ethanolamine salt; NEN), a drug approved by the US Food and Drug Administration (USFDA), is currently used as an anthelmintic drug for the treatment of parasitic infections. Recently, NEN was shown to improve hepatic steatosis in high-fat diet (HFD)-fed mice. However, the underlying mechanism of its antioxidant function in NASH remains unknown. Here, we demonstrate that NENinduces AMPK-mediated phosphorylation of p62 at S351 that can lead to noncanonical Nrf2 activation. We also demonstrate that NENprotects cells and mouse liver from acute lipotoxic stress through activating p62-dependent Keap1-Nrf2 pathway. Taken together, NEN can be used for clinical applications and has the potential to provide a new therapeutic option for NASH.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Science-
dc.relation.isPartOfFREE RADICAL BIOLOGY AND MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleRepositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentBioMedical Science Institute (의생명과학부)-
dc.contributor.googleauthorJeong Su Park-
dc.contributor.googleauthorYu Seol Lee-
dc.contributor.googleauthorDa Hyun Lee-
dc.contributor.googleauthorSoo HanBae-
dc.identifier.doi10.1016/j.freeradbiomed.2019.04.030-
dc.contributor.localIdA01645-
dc.contributor.localIdA01798-
dc.contributor.localIdA01798-
dc.relation.journalcodeJ00906-
dc.identifier.eissn1873-4596-
dc.identifier.pmid31035006-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0891584919302837-
dc.subject.keywordLipotoxicity-
dc.subject.keywordNASH-
dc.subject.keyword NEN-
dc.subject.keywordNrf2-
dc.subject.keywordp62-
dc.contributor.alternativeNamePark, Jeong Su-
dc.contributor.affiliatedAuthor박정수-
dc.contributor.affiliatedAuthor배수한-
dc.contributor.affiliatedAuthor배수한-
dc.citation.volume137-
dc.citation.startPage143-
dc.citation.endPage157-
dc.identifier.bibliographicCitationFREE RADICAL BIOLOGY AND MEDICINE, Vol.137 : 143-157, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.